Arthur Zaske & Associates’s ResMed RMD Stock Holding History

Arthur Zaske & Associates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$236K	Hold	2,787	–	–	0.26%	73
2017 Q3	$214K	Hold	2,787	–	–	0.23%	76
2017 Q2	$217K	Buy	+2,787	New	+$199K	0.19%	71

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Arthur Zaske & Associates's RMD Position: Q4 2017 in Review

Arthur Zaske & Associates held its ResMed (RMD) position steady in Q4 2017 at 2,787 shares worth $236K. The position accounts for 0.26% of the portfolio, ranked #73.

Arthur Zaske & Associates first reported a position in RMD in Q2 2017 and has held it in 3 quarters since. 415 funds tracked by Wall St. Rank hold RMD as of Q4 2017.

Arthur Zaske & Associates held 2,787 shares of ResMed worth $236K as of Q4 2017.
Arthur Zaske & Associates left its ResMed share count unchanged in Q4 2017.
ResMed made up 0.26% of Arthur Zaske & Associates's portfolio in Q4 2017, its #73 holding.
Arthur Zaske & Associates first reported a position in ResMed in Q2 2017 and has held it in 3 quarters since.
415 funds tracked by Wall St. Rank held ResMed as of Q4 2017.

Based on Arthur Zaske & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.